According to the research report titled ‘United States Influenza Vaccines Market Forecast 2020 – 2027’, available with MarketStudyReport, United States influenza vaccines market is projected to observe considerable growth over 2021-2027, reaching a valuation of USD 5.1 billion by the end of the forecast period.
 

United States influenza vaccines market growth can be attributed to rising prevalence of influenza epidemic and seasonal outbreaks, boosting the product demand and sales.
 

Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/2857054/
 

For the uninitiated, influenza is a viral infection that affects the respiratory system and is caused by the flu virus. The influenza virus is infectious and spreads through respiratory droplets. It can also be transmitted from one person to another during conversation or via physical touch.
 

Growth in technological advancements, emergence of new vaccines, and shifting government focus on immunization programs are propelling the market expansion.
 

Moreover, increasing research & development activities, surge in the COVID-19 cases, rising disease cognizance, along with government and advisory bodies recommendation to be vaccinated against such ailments are defining United States influenza vaccines industry scope.
 

The report thoroughly analyzes the number of children and adults vaccinated with influenza vaccines with next seven-year forecast. It also assesses the distribution channel and offers a detailed account of the distribution and demand in the country.
 

Speaking of challenges plaguing the industry expansion, influenza viruses evolve from year to year, thus influenza vaccines must be updated every year to contain the viruses that are most likely to circulate in the coming season.
 

Following the selection of the viruses for the new formulation, manufacturers must produce, test, release, and distribute the vaccine within a very short time frame. Due to these time limits, any production issues could result in shortages or delays, hence acting as major challenge for industry producers.
 

Major players operating in United States influenza vaccines market sphere are AstraZeneca plc, Seqirus, GlaxoSmithKline (GSK) plc, Sanofi Pasteur, BiondVax Pharmaceuticals Ltd., and Novavax Inc. among others.
 

The document entails strategic developments undertaken by the key industry players to sustain their market share and boost income flow. For instance, Emergent BioSolutions Inc. signed an agreement with Novavax Inc. to manufacture NanoFlu in March 2020. Similarly, in August 2021, AstraZeneca announced shipment of FluMist Quadrivalent doses for 2020-2021 flu season.